Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)

Breast Cancer Clinical Trial

Official title:

A Randomized Double-Blind Phase-2 Study of Anastrozole Plus Lonafarnib (SCH 66336) or Anastrozole Plus Placebo for the Treatment of Subjects With Advanced Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00081510
• Other study ID #: P03480
• Status: Completed
• Phase: Phase 2
• First received: April 14, 2004
• Last updated: March 26, 2015
• Start date: December 2003
• Est. completion date: May 2009

Study information

• Verified date: March 2015
• Source: Merck Sharp & Dohme Corp.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Primary Objective(s):

• To compare the activity (progression-free survival [PFS]) of anastrozole in combination with lonafarnib to that of anastrozole in combination with placebo in subjects with hormone-sensitive ADVANCED breast cancer.

Secondary Objective(s):

• To determine the effects of anastrozole in combination with lonafarnib on objective response, duration of response, overall survival, and safety in subjects with advanced breast cancer. To assess the exposure and pharmacokinetics of lonafarnib and anastrozole in the subject population.

Other known NCT identifiers

• NCT00098904

Recruitment information / eligibility

• Status: Completed
• Enrollment: 110
• Est. completion date: May 2009
• Est. primary completion date: May 2009
• Accepts healthy volunteers: No
• Gender: Female
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Postmenopausal women who have histologically-confirmed breast cancer with the following characteristics:

• estrogen and/or progesterone receptor positive,

• locally advanced disease

• distant metastatic disease, stage 4

• Subjects eligible for single-agent treatment with aromatase inhibitors for current disease.

• Subjects taking biophosphonates are allowed if they begin bisphosphonate therapy AT LEAST two weeks prior to randomization.

• Measurable disease (masses with clearly defined margins on radiological images and at least one diameter >=20 mm[>=10 mm if spiral CT]) or evaluable disease (masses with margins not clearly defined on radiological images or with no diameter >= 20 mm). Subjects with bone disease only are permitted if disease is evaluable.

• ECOG Performance Status of 0 or 1.

• Sufficient bone marrow reserve.

• Adequate hepatic and renal function: laboratory values within protocol requirements.

Exclusion Criteria:

• Subjects who have received more than one regimen of cytotoxic chemotherapy for advanced disease.

• Subjects with with CLINICALLY APPARENT brain metastases or extensive visceral disease, including extensive hepatic involvement or pulmonary lymphangitic spread of tumor.

• Subjects with prior treatments with FTIs.

• Subjects with a known or suspected hypersensitivity to any excipients in the lonafarnib formulation (Providone, Poloxamer 188, croscarmellose sodium, silicon dioxide, and magnesium stearate).

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• Lonafarnib

• Placebo

• anastrozole

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Merck Sharp & Dohme Corp.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival (PFS)		When approximately 70 subjects have progressed	No
Secondary	Objective response rate (adjusted RECIST criteria), duration of response, and overall survival		When approximately 70 subjects have progressed	Yes
Secondary	To access the exposure and pk of lonafarnib and anastrazole in the subject population.		When approximately 70 subjects have progressed	Yes